Mesoblast (MESO) vs Recursion Pharmaceuticals (RXRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Recursion Pharmaceuticals (RXRX) has outperformed Mesoblast (MESO) over the past year, losing 18.4% versus a loss of 22.9%. Over five years, MESO leads with a +22.7% price change compared with -77.6% for RXRX. Recursion Pharmaceuticals is the larger company by market cap ($2.29 billion vs $1.81 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MESO | RXRX |
|---|---|---|
| Share price | $13.94 | $4.27 |
| Market cap | $1.81B | $2.29B |
| 1-day change | +2.42% | -7.78% |
| YTD return | -22.73% | +4.40% |
| 1-year return | -22.94% | -18.36% |
| 5-year return | +22.71% | -77.57% |
| Forward P/E | 30.64 | — |
| EPS (TTM) | $-0.45 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $21.50 | $7.18 |
| 52-week low | $13.05 | $2.77 |
| Distance from 52-week high | -35.16% | -40.53% |
| Analyst consensus | buy | none |
| Avg. price target upside | +165.42% | +69.09% |
| Average volume | 236.60K | 20.24M |
| Shares outstanding | 129.85M | 535.34M |
| Employees | 108 | 600 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
About Recursion Pharmaceuticals
RXRX stock →Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 600 employees
MESO vs RXRX FAQ
Which is bigger, Mesoblast or Recursion Pharmaceuticals?
Recursion Pharmaceuticals (RXRX) is larger, with a market capitalization of $2.29B compared with $1.81B for Mesoblast (MESO).
Which stock has performed better over the past year, MESO or RXRX?
RXRX returned -18.36% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Mesoblast and Recursion Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.